✨ Free AI Report
Merck & Co., Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Merck & Co., Inc.
Company Research

Merck & Co., Inc.: Business Overview, Financials & Competitive Analysis

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. For more than 130 years, the comp...

Analyst-debate audio for Merck & Co., Inc.

AskCyborg analysts argue the bull and bear cases for Merck & Co., Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

Merck is a diversified pharmaceutical leader navigating Keytruda patent expiration through strategic acquisitions, cost...

Read the full analyst-debate transcript →
Industry Pharmaceuticals & Biopharmaceuticals
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 26, 2026
AI-Generated Research
30+ Page Report

Get the Latest Merck & Co., Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Merck & Co., Inc. Overview

Pro stress-test →

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. For more than 130 years, the company has brought hope to humanity through the development of important medicines and vaccines.

Strategic Profile

Pro stress-test →

Merck's 2026 narrative is centered on Keytruda, the world's top-selling cancer drug. The market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition. The transformation of the company's portfolio, bolstered by the acquisitions of Verona Pharma and Cidara Therapeutics, is well underway, with momentum building as it continues to execute on its strategy.

Competitive Landscape

Pro stress-test →

Merck competes in the global pharmaceutical and vaccine markets against major players including Pfizer, AbbVie, Gilead Sciences, Eli Lilly, Johnson & Johnson, and other pharmaceutical companies. The company faces competitive pressures from generic alternatives, biosimilars, and newer competitors in oncology, vaccines, and specialty care. Merck differentiates through its oncology portfolio leadership (Keytruda), vaccine strength (Gardasil, M-M-R II), and emerging pipeline candidates.

Industry Context

Merck & Co., Inc. operates in Pharmaceuticals & Biopharmaceuticals.

Key facts

Founded: 1891 · Headquarters: Rahway, US · Revenue: $65.0B · Market cap: $268.4B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Merck & Co., Inc..

  • Keytruda sales reached $8.37 billion in Q4, rising 7% year-over-year, driven by uptake for earlier-stage cancers and strong demand for metastatic cancer treatment.
  • Newer drug Winrevair, used to treat pulmonary arterial hypertension, recorded $467 million in sales for the quarter, up 133% from the same period a year earlier.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026FDA approved Keytruda for platinum-resistant carcinomas expansion
  • January 2026Completed $221.50 per share acquisition of Cidara Therapeutics
  • +2 moreTrack every material event for Merck & Co., Inc. as it happens. Explore monitoring →
Get alerted when Merck & Co., Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

KeytrudaCheckpoint inhibitor for oncology applications→OpdivoCompeting immunotherapy for cancer→TecentriqPD-L1 inhibitor for multiple cancer types→Pharamacuetical PortfolioDiversified global pharma competitor→

Compare Merck & Co., Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Merck & Co., Inc. operates in Pharmaceuticals & Biopharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals & Biopharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Merck & Co., Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Merck & Co., Inc. and its top competitor on Cyborg Score”
“What did Merck & Co., Inc. do this quarter?”
“Is Merck & Co., Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Merck & Co., Inc. do?+
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. For more than 130 years, the comp...
What is Merck & Co., Inc.'s Cyborg Score?+
Merck & Co., Inc. has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Merck & Co., Inc.'s main competitors?+
Named competitors include Keytruda, Opdivo, Tecentriq, Pharamacuetical Portfolio. The full competitive landscape is in the AskCyborg report.
How can I get the full Merck & Co., Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Merck & Co., Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Merck & Co., Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals & Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Chugai Pharmaceutical Co., Ltd.7Merck & Co., Inc.